Blueberry Therapeutics and LSTM are awarded an MRC Confidence in Concept grant to explore nano-formulations of Ceftriaxone for the treatment of Typhoid fever.
Dave Cook, Chief Scientific Officer at Blueberry said “We’re delighted to be working with the team at LSTM on this exciting project. Typhoid fever is a major human health issue and so exploring the potential application of our nano-formulations to improve antibiotic therapy is an important first step in improving treatment of the disease.”
The MRC Confidence in Concept (CiC) scheme provides funding to institutions to support the earliest stages of translational research projects. More details can be found using the link below